JP7287607B6 - 神経筋障害の治療のためのフェノキシ酸 - Google Patents

神経筋障害の治療のためのフェノキシ酸 Download PDF

Info

Publication number
JP7287607B6
JP7287607B6 JP2020532570A JP2020532570A JP7287607B6 JP 7287607 B6 JP7287607 B6 JP 7287607B6 JP 2020532570 A JP2020532570 A JP 2020532570A JP 2020532570 A JP2020532570 A JP 2020532570A JP 7287607 B6 JP7287607 B6 JP 7287607B6
Authority
JP
Japan
Prior art keywords
alkyl
group
propanoic acid
bromo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020532570A
Other languages
English (en)
Japanese (ja)
Other versions
JP7287607B2 (ja
JP2021506787A (ja
JP2021506787A5 (https=
Inventor
ジェイ．エス．クヌッセン，ラース
ケリー，ニコラス
ペデルセン，トーマス ホルム
オルセン，クラウス エルスボルグ
ラベル，マーク
リトル，ポール，ブライアン
クーパー，マーティン イー
サラスワット，ニールジャー
ドゥデクラ，ダスタギリ
エー．タジェ，ラフィク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NMD Pharma AS
Original Assignee
NMD Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NMD Pharma AS filed Critical NMD Pharma AS
Publication of JP2021506787A publication Critical patent/JP2021506787A/ja
Publication of JP2021506787A5 publication Critical patent/JP2021506787A5/ja
Publication of JP7287607B2 publication Critical patent/JP7287607B2/ja
Application granted granted Critical
Publication of JP7287607B6 publication Critical patent/JP7287607B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020532570A 2017-12-14 2018-12-14 神経筋障害の治療のためのフェノキシ酸 Active JP7287607B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598959P 2017-12-14 2017-12-14
US62/598,959 2017-12-14
EP18151651 2018-01-15
EP18151651.9 2018-01-15
PCT/EP2018/084988 WO2019115780A1 (en) 2017-12-14 2018-12-14 Phenoxy acids for the treatment of neuromuscular disorders

Publications (4)

Publication Number Publication Date
JP2021506787A JP2021506787A (ja) 2021-02-22
JP2021506787A5 JP2021506787A5 (https=) 2021-12-16
JP7287607B2 JP7287607B2 (ja) 2023-06-06
JP7287607B6 true JP7287607B6 (ja) 2024-02-19

Family

ID=64664308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020532570A Active JP7287607B6 (ja) 2017-12-14 2018-12-14 神経筋障害の治療のためのフェノキシ酸

Country Status (10)

Country Link
EP (1) EP3723746B1 (https=)
JP (1) JP7287607B6 (https=)
CN (1) CN111491628B (https=)
AU (1) AU2018383005B2 (https=)
CA (1) CA3085227C (https=)
DK (1) DK3723746T3 (https=)
ES (1) ES2911895T3 (https=)
MX (1) MX2020005471A (https=)
TW (1) TW201927738A (https=)
WO (1) WO2019115780A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025637A2 (pt) 2019-06-19 2022-02-01 Nmd Pharma As Compostos para o tratamento de doenças neuromusculares
CN113072420B (zh) * 2021-02-23 2022-05-20 中山大学 一类2-芳基取代的偕二氟环丁烷类化合物及其制备方法
EP4731200A1 (en) 2023-06-20 2026-04-29 NMD Pharma A/S Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202341A1 (en) 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
JP6199991B2 (ja) * 2013-01-18 2017-09-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ３置換ピラゾール及びｄｌｋ阻害剤としての使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202341A1 (en) 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders

Also Published As

Publication number Publication date
CN111491628A (zh) 2020-08-04
CA3085227A1 (en) 2019-06-20
JP7287607B2 (ja) 2023-06-06
EP3723746B1 (en) 2022-02-23
EP3723746A1 (en) 2020-10-21
ES2911895T3 (es) 2022-05-23
AU2018383005B2 (en) 2024-04-04
AU2018383005A1 (en) 2020-07-09
CN111491628B (zh) 2023-10-13
CA3085227C (en) 2025-06-17
DK3723746T3 (da) 2022-05-23
JP2021506787A (ja) 2021-02-22
WO2019115780A1 (en) 2019-06-20
TW201927738A (zh) 2019-07-16
MX2020005471A (es) 2020-08-27

Similar Documents

Publication Publication Date Title
CN107820425B (zh) 用于治疗神经肌肉病症的化合物
TWI794369B (zh) 用於治療神經肌肉病症的化合物
EP3724173B1 (en) Compounds for the treatment of neuromuscular disorders
JP7287607B6 (ja) 神経筋障害の治療のためのフェノキシ酸
EP3753560A1 (en) Compounds for the treatment of neuromuscular disorders
US12415771B2 (en) Compounds for the treatment of neuromuscular disorders
US12168643B2 (en) Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) Compounds for the treatment of neuromuscular disorders
US20190183812A1 (en) Compounds For The Treatment Of Neuromuscular Disorders
US11591284B2 (en) Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) Compounds for the treatment of neuromuscular disorders
CA3085233C (en) Compounds for the treatment of neuromuscular disorders
HK40029101A (en) Compounds for the treatment of neuromuscular disorders
HK40029101B (en) Compounds for the treatment of neuromuscular disorders

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230515

R150 Certificate of patent or registration of utility model

Ref document number: 7287607

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150